Advertisement

Annals of Nuclear Medicine

, Volume 31, Issue 8, pp 623–628 | Cite as

Comparison of Bayesian penalized likelihood reconstruction versus OS-EM for characterization of small pulmonary nodules in oncologic PET/CT

  • Brandon A. HowardEmail author
  • Rustain Morgan
  • Matthew P. Thorpe
  • Timothy G. Turkington
  • Jorge Oldan
  • Olga G. James
  • Salvador Borges-Neto
Original Article

Abstract

Objective

To determine whether the recently introduced Bayesian penalized likelihood PET reconstruction (Q.Clear) increases the visual conspicuity and SUVmax of small pulmonary nodules near the PET resolution limit, relative to ordered subset expectation maximization (OS-EM).

Methods

In this institutional review board-approved and HIPAA-compliant study, 29 FDG PET/CT scans performed on a five-ring GE Discovery IQ were retrospectively selected for pulmonary nodules described in the radiologist’s report as “too small to characterize”, or small lung nodules in patients at high risk for lung cancer. Thirty-two pulmonary nodules were assessed, with mean CT diameter of 8 mm (range 2–18). PET images were reconstructed with OS-EM and Q.Clear with noise penalty strength β values of 150, 250, and 350. Lesion visual conspicuity was scored by three readers on a 3-point scale, and lesion SUVmax and background liver and blood pool SUVmean and SUVstdev were recorded. Comparison was made by linear mixed model with modified Bonferroni post hoc testing; significance cutoff was p < 0.05.

Results

Q.Clear improved lesion visual conspicuity compared to OS-EM at β = 150 (p < 0.01), but not 250 or 350. Lesion SUVmax was increased compared to OS-EM at β = 150 and 250 (p < 0.01), but not 350.

Conclusion

In a cohort of small pulmonary nodules with size near an 8 mm PET full-width half maximum, Q.Clear significantly increased lesion visual conspicuity and SUVmax compared to our standard non- time-of-flight OS-EM reconstruction, but only with low noise penalization. Q.Clear with β = 150 may be advantageous when evaluation of small pulmonary nodules is of primary concern.

Keywords

FDG PET PET/CT Penalized likelihood reconstruction Oncology 

Notes

Acknowledgements

The authors would like to thank Priti Patel, CNMT for her assistance with the PET reconstructions and Steve Ross, PhD of GE Healthcare for his invaluable comments and suggestions regarding this work.

Compliance with ethical standards

Conflict of interest

Brandon Howard, MD, PhD, Rustain Morgan, MD, Matthew Thorpe, MD, Timothy Turkington, MD, Jorge Oldan, MD and Olga James, MD—no conflict of interest to disclose. Salvador Borges-Neto, MD—research grant from GE Healthcare, which did not fund any portion of the research described in this manuscript.

References

  1. 1.
    Garcia-Velloso MJ, Bastarrika G, de-Torres JP, Lozano MD, Sanchez-Salcedo P, Sancho L, et al. Assessment of indeterminate pulmonary nodules detected in lung cancer screening: diagnostic accuracy of FDG PET/CT. Lung Cancer. 2016;97:81–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Verhagen AF, Bootsma GP, Tjan-Heijnen VC, van der Wilt GJ, Cox AL, Brouwer MH, et al. FDG-PET in staging lung cancer: how does it change the algorithm? Lung Cancer. 2004;44:175–81.CrossRefPubMedGoogle Scholar
  3. 3.
    Grootjans W, de Geus-Oei LF, Meeuwis AP, van der Vos CS, Gotthardt M, Oyen WJ, et al. Amplitude-based optimal respiratory gating in positron emission tomography in patients with primary lung cancer. Eur Radiol. 2014;24:3242–50.CrossRefPubMedGoogle Scholar
  4. 4.
    Vriens D, Visser EP, de Geus-Oei LF, Oyen WJ. Methodological considerations in quantification of oncological FDG PET studies. Eur J Nucl Med Mol Imaging. 2010;37:1408–25.CrossRefPubMedGoogle Scholar
  5. 5.
    Asma E, Ahn S, Ross S, Chen A, Manjeshwar R. Accurate and consistent lesion quantitation with clinically acceptable penalized likelihood images. IEEE Nuclear Science Symposium Conference Record 2012.Google Scholar
  6. 6.
    Moyer VA, Force USPST. Screening for lung cancer: U.S. Preventive services task force recommendation statement. Ann Intern Med. 2014;160:330–8.PubMedGoogle Scholar
  7. 7.
    Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508.CrossRefPubMedGoogle Scholar
  8. 8.
    Cherry SR, Sorenson JA, Phelps ME. Physics in nuclear medicine. 4th ed. Philadelphia: Elsevier/Saunders; 2012.Google Scholar
  9. 9.
    Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR. 2010;31:496–505.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging. 1994;13:601–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Ahn S, Ross SG, Asma E, Miao J, Jin X, Cheng L, et al. Quantitative comparison of OSEM and penalized likelihood image reconstruction using relative difference penalties for clinical PET. Phys Med Biol. 2015;60:5733–51.CrossRefPubMedGoogle Scholar
  12. 12.
    Teoh EJ, McGowan DR, Macpherson RE, Bradley KM, Gleeson FV. Phantom and clinical evaluation of the Bayesian penalized likelihood reconstruction algorithm Q.Clear on an LYSO PET/CT system. J Nucl Med. 2015;56:1447–52.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Teoh EJ, McGowan DR, Bradley KM, Belcher E, Black E, Gleeson FV. Novel penalised likelihood reconstruction of PET in the assessment of histologically verified small pulmonary nodules. Eur Radiol. 2016;26:576–84.CrossRefPubMedGoogle Scholar
  14. 14.
    Teoh EJ, McGowan DR, Bradley KM, Belcher E, Black E, Moore A, et al. 18F-FDG PET/CT assessment of histopathologically confirmed mediastinal lymph nodes in non-small cell lung cancer using a penalised likelihood reconstruction. Eur Radiol 2016;26:4098–4106CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    MacMahon H, Austin JH, Gamsu G, Herold CJ, Jett JR, Naidich DP, et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology. 2005;237:395–400.CrossRefPubMedGoogle Scholar
  16. 16.
    Gore RM, Thakrar KH, Wenzke DR, Newmark GM, Mehta UK, Berlin JW. That liver lesion on MDCT in the oncology patient: is it important? Cancer Imaging. 2012;12:373–84.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Parvizi N, Franklin JM, McGowan DR, Teoh EJ, Bradley KM, Gleeson FV. Does a novel penalized likelihood reconstruction of 18F-FDG PET-CT improve signal-to-background in colorectal liver metastases? Eur J Radiol. 2015;84:1873–8.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Nuclear Medicine 2017

Authors and Affiliations

  • Brandon A. Howard
    • 1
    Email author
  • Rustain Morgan
    • 1
    • 2
  • Matthew P. Thorpe
    • 1
  • Timothy G. Turkington
    • 1
  • Jorge Oldan
    • 3
  • Olga G. James
    • 1
  • Salvador Borges-Neto
    • 1
  1. 1.Division of Nuclear Medicine, Department of RadiologyDuke University Medical CenterDurhamUSA
  2. 2.Division of Nuclear Medicine and Molecular Imaging, Department of RadiologyUniversity of Colorado Anschutz Medical CampusAuroraUSA
  3. 3.Department of RadiologyUniversity of North Carolina-Chapel HillChapel HillUSA

Personalised recommendations